Inquiry List

* Name:
* Phone:
* Service & Products of Interested: [Deuterium] 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropane-2,2,3,3-[d4]-carboxylic Acid (1961281-89-9)
Project Description:
* Quantity
* Email:
* Organization We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
* Verification Code:

Our Highlights

Optimal Prices
Buying products on this site guarantees the best price
Flexible Batches
Flexible batch size to meet different needs of global customers
Prompt Delivery
Warehouses in multiple cities to ensure timely delivery
Quality Assurance
Strict process parameter control to ensure product quality
One-to-one Customization
One-to-one custom synthesis for special structural needs

Application Area

Environmental

Stable isotope-labeled compounds are used as environmental pollutant standards for the detection of air, water, soil, sediment and food.

Clinical diagnostic

In addition to treating various diseases, isotopes are used for imaging, diagnosis, and newborn screening.

Organic Chemistry

Small molecule compounds labeled with stable isotopes can be used as chemical reference for chemical identification, qualitative, quantitative, detection, etc. Various types of NMR solvents can be used to study the structure, reaction mechanism and reaction kinetics of compounds.

Metabolic Research

Stable isotope labeling allows researchers to study metabolic pathways in vivo in a safe manner.

1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropane-2,2,3,3-[d4]-carboxylic Acid

Inquiry

General Information
Catalog: BLP-020986
CAS: 1961281-89-9
Molecular Formula: C11H4D4F2O4
Molecular Weight: 246.2

Chemical Structure

Description

1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropane-2,2,3,3-d4-carboxylic Acid is an intermediate in the synthesis of Tezacaftor-D4 (T321512), an isotope labelled compound of Tezacaftor (T321510). Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis.